Nov 29 2010
Zalicus Inc. (NASDAQ: ZLCS) announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.
“ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma”
"These data reinforce the rationale for investigation of A2A agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the Zalicus combination high throughput screening (cHTS™) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application," commented Mark H.N. Corrigan, M.D., President and CEO of Zalicus Inc. "Zalicus is continuing to leverage the power of its proprietary cHTS technology through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaborations with Clinical Data, Inc. and Novartis."
- Sunday, December 5, 2010, 6:00-8:00 p.m., Poster session I: Myeloma - Pathophysiology and Preclinical Studies, excluding Therapy.
#2990, Poster Board II-870, "ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma", Rickles, et al, Orange County Convention Center, Hall A3/A4.
ATL313 is a potent and selective A2A agonist being evaluated by Zalicus and PGxHealth, LLC, a division of Clinical Data, Inc., for the treatment of B-cell cancers, including multiple myeloma. ATL313 is also being evaluated by Clinical Data, Inc. and its other collaborators for a number of indications including glaucoma, chronic pain, multiple sclerosis and atherosclerosis.
Source: Zalicus Inc.
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes